Literature DB >> 22010848

How do we define congenital heart defects for scientific studies?

Ester Garne1, Morten Smaerup Olsen, Søren Paaske Johnsen, Vibeke Hjortdal, Henrik Ørbaek Andersen, Henrik Nissen, Lars Søndergaard, Jørgen Videbaek.   

Abstract

Estimates of the prevalence of congenital heart defects (CHD) have been published over many years and from many regions. As they are based on different definitions of which cases to include in the CHD prevalence, published prevalence estimates vary substantially. With the increasing use of echocardiography in neonatal intensive care, a patent ductus arteriosus (PDA) or flow over the atrial septum will often be visible. These findings may be coded as CHD at discharge and in this way falsely increase the CHD prevalence in the population. There are several purposes for which population-based data on CHD may be used: etiology, planning of treatment, or obtain information on outcome, including mortality. For etiology studies, it is important to include terminations of pregnancy as well as all births with CHD. For mortality studies in live births, inclusion of preterm born infants with PDA will increase overall mortality of CHD. The Danish Register of Congenital Heart Disease is based on hospital discharge diagnoses and diagnoses from outpatient visits. To increase the validity of these data, extensive data cleaning has been carried out based on record review and knowledge on the discharge coding practice. We include PDA and atrial septal defects as CHD cases if these defects are still open 2 months after birth. International consensus on how to define CHD would improve the validity and comparability of epidemiological studies on CHD.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22010848     DOI: 10.1111/j.1747-0803.2011.00581.x

Source DB:  PubMed          Journal:  Congenit Heart Dis        ISSN: 1747-079X            Impact factor:   2.007


  7 in total

1.  Identification of adults with congenital heart disease of moderate or great complexity from administrative data.

Authors:  Jill M Steiner; James N Kirkpatrick; Susan R Heckbert; Asma Habib; James Sibley; William Lober; J Randall Curtis
Journal:  Congenit Heart Dis       Date:  2017-07-24       Impact factor: 2.007

2.  Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy--an epidemiological study using validated EUROCAT data.

Authors:  Tanja Majbrit Knudsen; Anne Vinkel Hansen; Ester Garne; Anne-Marie Nybo Andersen
Journal:  BMC Pregnancy Childbirth       Date:  2014-09-25       Impact factor: 3.007

Review 3.  Atrazine and pregnancy outcomes: a systematic review of epidemiologic evidence.

Authors:  Michael Goodman; Jack S Mandel; John M DeSesso; Anthony R Scialli
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2014-05-02

4.  KinCor, a national registry for paediatric patients with congenital and other types of heart disease in the Netherlands: aims, design and interim results.

Authors:  L M Silva; I M Kuipers; F van den Heuvel; R Mendes; R M F Berger; I M van Beynum; L Rozendaal; L A J Rammeloo; G G van Iperen; M Schokking; S Frerich; N A Blom; J M P J Breur; W A Helbing
Journal:  Neth Heart J       Date:  2016-11       Impact factor: 2.380

5.  Heart disease among Greenlandic children and young adults: a nationwide cohort study.

Authors:  Marie Tindborg; Anders Koch; Mikael Andersson; Klaus Juul; Uka Wilhjelm Geisler; Bolette Soborg; Sascha Wilk Michelsen
Journal:  Int J Epidemiol       Date:  2022-10-13       Impact factor: 9.685

6.  Targeted inactivation of Cerberus like-2 leads to left ventricular cardiac hyperplasia and systolic dysfunction in the mouse.

Authors:  Ana Carolina Araújo; Sara Marques; José António Belo
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

7.  Insulin analogues use in pregnancy among women with pregestational diabetes mellitus and risk of congenital anomaly: a retrospective population-based cohort study.

Authors:  Hao Wang; Ewa Wender-Ozegowska; Ester Garne; Margery Morgan; Maria Loane; Joan K Morris; Marian K Bakker; Miriam Gatt; Hermien de Walle; Susan Jordan; Anna Materna-Kiryluk; Vera Nelen; Guy Thys; Awi Wiesel; Helen Dolk; Lolkje T W de Jong-van den Berg
Journal:  BMJ Open       Date:  2018-02-24       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.